tion with a chemotherapeutic agent, an effect on melanoma cell viability in vitro.
Only a small fraction (4.3%) of our 102 melanoma biobank cell lines with RNAsequencing data showed expression of the main receptor for Met (OPRM1). We as- 
K E Y W O R D S
cisplatin, melanoma, methadone, OPRM1 melanoma cell lines and/or (ii) indirectly sensitize melanoma cells to chemotherapeutic agents such as Cis.
| E XPERIMENTAL DE S I G N
Details on the subsequently described methods, cell lines and reagents are given in Data S1.
| Cell lines, Chemicals
Patients gave their written informed consent approved by the local institutional review board (EK647/800). Primary melanoma cell cultures were established from metastatic melanoma tissue as previously described.
[10]
| Cell viability assay
The cell lines were challenged with dose-escalating concentrations of Met alone, Cis alone, Cis/Met combined, an ERK-inhibitor or ERKinhibitor/Met combined for 72 hours. Cell viability was estimated using a fluorometric (resazurin) assay.
| Immunohistochemistry stainings
Immunohistochemical stainings were performed as previously described. [11] We used an anti-OPRM1 antibody (PA5-26138; Thermo
Fisher Scientific, Reinach, Switzerland); negative controls were obtained by substituting rabbit IgG for the primary antibody.
| RE SULTS

| OPRM1 is lowly expressed in most melanoma cell lines
Met binds to OPRM1, acting as an agonist. We first assess OPRM1 Figure 1A ).
Immunohistochemistry stainings confirmed the expression of OPRM1 at the protein level ( Figure 1B ).
| Met treatment does not significantly affect melanoma cell viability
To investigate the effects of Met on these melanoma cell lines with regard to viability, we treated them with Met, Cis (positive control), medium (negative control) or a combination of Cis/Met using dose- Whereas in various cancer types, OPRM1 expression has been associated with higher staging and/or poor outcome, [8, [12] [13] [14] [15] our findings suggest this is not the case in melanoma. As to the effects of Met,
Friesen et al [2] [3] [4] had reported that apoptosis rates increased by about with TMZ/Met) showed a lack of effect in uveal melanoma.
In conclusion, it seems unlikely that combining Met with chemotherapy has a beneficial effect for patients with melanoma. Our findings do not provide evidence for recommending the use of Met as an adjuvant to chemotherapy to our patients with melanoma.
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